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ABSTRACT
A low pressure plasma process based on plasma deposition has been used to 
develop a drug delivery strategy. In this study, a drug delivery system based on 
different layers of plasma co-polymerized Poly ε-caprolactone-Polyethylene glycol 
(PCL-PEG) co-polymers was deposited on biocompatible substrates. Cis-platinum 
(118 μgm/cm2) was used as an anti-cancer drug and incorporated for local delivery 
of the chemotherapeutic agent. The co-polymer layers and their interaction with 
cancer cells were analyzed by scanning electron microscopy. Our study showed that 
the plasma-PCL-PEG coated cellophane membranes, in which the drug, was included 
did not modify the flexibility and appearance of the membranes. This system was 
actively investigated as an alternative method of controlling localized delivery of drug 
in vivo. The loading of the anti-cancer drug was investigated by UV-VIS spectroscopy 
and its release from plasma deposited implants against BALB/c mice liver tissues 
were analyzed through histological examination and apoptosis by TUNEL assay. The 
histological examination of liver tissues revealed that when the plasma-modified 
membranes encapsulated the cis-platinum, the Glisson’s capsule and liver parenchyma 
were damaged. In all cases, inflammatory tissues and fibrosis cells were observed 
in contact zones between the implant and the liver parenchyma. In conclusion, low 
pressure plasma deposited uniform nano-layers of the co-polymers can be used for 
controlled release of the drug in vivo.
INTRODUCTION
In the past several years interest in platinum drugs 
has increased due to their successful administration for 
the treatment of most disseminated cancers [1]. Cis-
platinum (cis-diaminedichloroplatinum (II)) remains 
one of the most widely used and potent anticancer 
agents against many different types of cancer [2–3]. 
Cis-platinum exerts its anticancer effects by covalently 
binding to DNA and forming various platinum-DNA 
adducts which cause distortions in DNA and that leads to 
final cellular outcome of apoptotic cell death [4]. For the 
cancer treatment, cis-platinum is usually intravenously 
administered but it is often unsuccessful because of the 
nonselective distribution of the drug among the normal 
and tumor tissue and that likely enhances the risk of dose 
limiting side effects including chronic neurotoxicity, 
acute nephrotoxicity and myelosuppression [5–6]. After 
24 hrs of clinical administration of cis-platinum, it has 
been noticed that more than 65% of the platinum in the 
blood was protein bound, leading to severe side effects 
of cis-platinum treatment and therefore less therapeutic 
efficacy [7] and resistance over the course of medication 
[8]. In order to overcome these therapeutic limitations by 
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cis-platinum treatment and other anticancer drugs, there 
is a clear incentive to develop new strategies for efficient, 
systematic and controlled release of cis-platinum for 
oncology.
Towards enhancement for the prevention of the 
systematic side effects of the chemotherapy, a wide range 
of strategies have been developed for a more selective 
delivery. The trend in drug delivery technology has 
been toward biodegradable polymer excipients requiring 
no follow-up surgical removal once the drug supply 
is depleted [9]. For instance, wet chemically prepared 
polymer based cis-platinum loaded drug delivery 
systems such as platinum encapsulated PLGA-b-PEG 
nanoparticles [10], liposomes [11], PEG-b-poly (amino 
acid)-based polymeric micelles [12], polymeric conjugates 
of γ-PGA–cis-platinum [13], pH sensitive Bi(PEG-PLA)-
Pt(IV) polymer-prodrug conjugates [14] etc. The recent 
advances in nanoparticle formulations of cis-platinum for 
therapeutic applications have been thoroughly surveyed 
and the clinical utility of cis-platinum conjugates have 
been investigated [15].
As compared to the wet processes [9–16], plasma 
polymerization is a catalyst and solvent free, dry, one 
step, highly controllable and environmentally benign 
process. Recently, the radio frequency (RF) plasma 
(co-) polymerization of different organic precursors for 
surface modifications of a variety of substrates have 
been summarized in order to tailor the physico-chemical 
properties of the substrates for mitigation of nonspecific 
adsorption of proteins, tunable biomolecule-surface 
interactions and controlled drug delivery applications 
[17, 18]. The synergetic role of plasma generated free 
radicals for tuning the surface properties of polymers and 
their applications have been discussed broadly for drug 
delivery, biomedical and tissue engineering [19].
The biodegradable and biocompatible PCL-co-PEG 
polymers with different cell adhesion and cell-repellent 
properties have been prepared on different flat substrates 
by gradually varying the partial pressure ratio of the 
monomers (ε-CL/DEGME) under the solvent and catalyst 
free low-pressure inductively excited RF plasma reactor 
[20–23]. Later, cis-platinum loaded multilayer of plasma 
was studied polymerized PCL-co-PEG coatings have been 
used to produce barrier layers on different flat surfaces 
(glass, Si wafer, etc.) for the controlled release of drug and 
the in vitro release of anticancer drug was investigated for 
the apoptosis of ovarian cancer cells [22].
In our previous works [20-23], we have reported 
how to develop a Drug Delivery System based on multiple 
layers composed of plasma copolymers deposited on 
glass, and Si wafer by the dry clean plasma process. 
The controlled drug delivery of anticancer drug was 
investigated in-vitro for the apoptosis of ovarian cancer 
cells [22]. Here the same drug delivery system was 
deposited on cellophane membranes and the controlled 
release of cis-platinum was studied in vivo.
RESULTS
UV-visible spectroscopic measurements for cis-
platinum loading
The loading of cis-platinum on plasma co-
polymerized cellophane substrates was determined by 
measuring the absorbance in the range of 200 – 500 nm 
using UV-Vis spectrometer. The absorption spectrum 
of 1mM cis-platinum in 1X PBS, pH 7, is shown in 
Figure 1. Because of metal to ligand charge transfer 
(MLCT) transitions in cis-platinum solution [23], a strong 
band at 203 nm and a shoulder at 229 nm are appeared. 
Cis-platinum compound exhibits a much weaker band at 
330 nm which is assigned to the d-d transition of Pt2+ ions.
Cell-membrane contact analysis by scanning 
electron microscopy
As presented in Figure 2A, uniform copolymer 
layer (UCL) is intact and posed correctly on the substrate. 
Ovarian cancer cell line OVCAR-3 adhered on the UCL 
in the cell culture condition and do not perturbed by 
culture medium. Adhered cells form the filopodias on 
the membrane (Figure 2B). Incorporation of cis-platinum 
strongly modified the physiological properties of UCL by 
induction of cells detachment (Figure 2C). As presented 
in Figure 2D, the cellular debris remained after cell death 
on the UCL.
Influence of multilayer coatings membrane 
implants on the liver parenchyma
In our previously published work [22], the cis-
platinum loaded plasma polymerized multilayer PCL-
co-PEG coatings was assessed in vitro using human 
ovarian carcinoma cells (NIH: OVCAR-3) where it has 
been demonstrated that controlled release of cis-platinum 
was effectively induced apoptosis. Herein, after 10 days 
of hepatic implantation, the mice liver was extracted 
by surgical resection and histological measurements 
were performed (Figure 3). In Figure 3A, 1-3, the 
macroscopic and representative image of cellophane 
implanted animal, the position of the implant on the liver, 
magnified image showing surgically removed implant 
and representative image of histology are presented. 
Figure 3B, 1-4, histological examination of plasma 
deposited implants wrapped onto a liver, showed that 
the implants were properly positioned and surrounded 
by a fibrous capsule. This capsule was homogeneous 
along the whole perimeter of the plasma coated implants, 
with limited areas of necrosis and inflammatory cells. 
Several liver sections from this region were analysed for 
each case (Figure 3B, 1-4). Normal (3B-1) and the liver 
exposed to bare cellophane, unloaded drug membranes 
were presented in Figure 3B, 1-3. The liver is invested 
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Figure 1: UV absorption spectrum of 1 mM Cis-platinum in 1X PBS at pH 7.
Figure 2: interaction of ovarian cancer cell with uniform copolymer layer (UCL). Ovarian cancer cell line OVCAR-3 adhered 
on the UCL (arrow) in the culture medium (A. X2500). This interaction is biocompatible and adhered cell form the pseudopod and nanopod 
on the UCL (B. X20000). When the anti-cancer drug was incorporated, on the UCL, the cells shape changed (C. x10000) and adherent 
necro-apoptotic cell organelles (arrow) were observed after cells detachments (D. X5000).
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Figure 3: Macroscopic and microscopic observation of hepatic implantation of cellophane inBALB/c mice sacrificed 
on the 10th day. Macroscopic and representative image of cellophane implanted animal, magnified image showing surgically removed 
implant and representative image of histology A. Microscopic images for the histological analysis of normal liver tissues called of control 
B-1. liver exposed to untreated (uncoated) cellophane (Cello) B-2. plasma polymers + cellophane coated with copolymer without cis-
platinum (4B-3) cellophane (pPCL-co-PEG-Cello) B-3. cellophane coated with copolymer + drug and plasma polymers, + Cis-platinum + 
cellophane (Cisp-pPCL-co-PEG-Cello) B-4. Data are a typical microscopic imaging of liver tissue sections C. under original magnification 
of 20 X, 100 X and 200 X. Nuclei: dark blue, cytoplasm: pink. CV: Central vein.
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by a connective tissue capsule named Glisson’s capsule. 
The histological examination of the liver of the control 
mice exhibited the normal architecture of the liver 
whereas the parenchyma of the control liver specimens 
was uniform in appearance. As presented in Figures 3B-
2, when untreated cellophane was used, the Glisson’s 
capsule and liver parenchyma were intact after 10 days. 
In case of pPCL-co-PEG-cello, no significant change 
was observed in liver tissues as compared to control 
Figures 3B-3. That shows the plasma polymerized PCL-
co-PEG coatings on cellophane implants which were in 
contact with liver for 10 days, were biocompatible and 
did not generate significant inflammatory response. The 
histological appearance of parenchyma in pPCL-co-
PEG-Cello, and untreated cellophane was comparable 
with that of control group. On the contrary, when the 
membrane contained cis-platinum (Cisp-pPCL-co-PEG-
Cello,), the Glisson’s capsule and liver parenchyma 
were damaged (Figure 3B-4). In addition, the mice 
liver treated with the Cisp-pPCL-co-PEG-Cello, 
formulation did exhibit inflammatory cells as compared 
to the control. As compared to control, the histological 
examination of the liver tissues of the Cisp-pPCL-co-
PEG-Cello treated mice exhibited congestion of the 
central veins and intracytoplasmic vacuolations were 
observed which might be due to the cis-platinum induced 
oxidative damage and lipid peroxidation of the liver 
tissues [24]. In the cells around the central vein (arrow 
CV), the cytoplasmic modifications were observed. As 
shown in Figure 3C (magnification: 200X), the clusters 
of inflammatory cells were observed in the surrounding 
of portal region. In all implanted cases, the fibrosis was 
observed on the zones in contact with the implant and 
liver parenchyma showed by arrow (Figure 3C, 2-4).
Detection of apoptotic cells in liver tissues
In order to detect the apoptosis in the liver tissues, 
the TUNEL immunohistological assay was performed 
for different experimental groups (Figure 4). As shown 
in stained sections (Figure 4A and 4B), no significant 
morphological differences were observed in liver tissues 
from mice implanted with untreated cellophane (Figure 
4A) and plasma treated cellophane (Figure 4B). No 
apoptotic cells were observed with untreated cellophane 
(Cello) and pPCL-co-PEG-Cello. TUNEL positive (green 
florescence) signals were, however observed in liver tissues 
of mice wrapped with Cisp-pPCL-co-PEG-Cello implants 
for 10 days (Figure 4C). The magnified image of TUNEL 
positive cells in liver tissues is shown in Figure 4D.
Cis-platinum traces in blood plasma by 
ultraviolet-visible spectrophotometry
Preliminary studies were carried out to determine 
the traces of cis-platinum in the blood plasma in the 
broad ultraviolet-visible (UV-Vis) region ranging from 
200 to 500 nm. Initial studies were conducted using 0.2-
0.5 ml of blood plasma from experimental groups and 
control group in a quartz cuvette. As presented in Figure 
5, The UV-V of the spectrum of the blood plasma shows 
a strong band at 410 nm and a less intense band at 250 
nm attributed to the hemoglobin (Hb) and oxidized Hb 
respectively. In the case of Cisp-pPCL-co-PEG-Cello, 
a very weak peak corresponding to Pt+2 ion can be 
identified at 330 nm, even though it is not completely 
distinguishable from the rest of the spectra due to 
the overlapping. Therefore it is difficult to assign the 
absorption of platinum compounds in biological medium 
such as blood. One can note in Figure 2 which shows 
the UV absorption of cis-platinum in PBS, (Figure 5). It 
can be pointed out that the absorption spectrum of cis-
platinum in blood plasma (Figure 5) is quite different as 
compared to its absorption in PBS (Figure 2). Therefore 
it is difficult to assign absorption of platinum compounds 
in biological media such as blood.
DISCUSSION
In this study we described the in vivo local drug 
release efficacy of the low pressure plasma polymerized 
PCL-co-PEG encapsulated cis-platinum implants as 
biocompatible and biodegradable drug carriers. A drug 
delivery system based on different layers presenting 
different chemical compositions of PCL-PEC copolymers 
obtained by low pressure plasma has been already 
reported [22]. The total thickness of these layers is in the 
order of a few hundreds of nm. However the first layers 
deposited to increase the affinity of the membrane is a 
few tens of nm, followed by a dense barrier deposited 
at higher powers, covered again by coatings under 
conditions which would be cell nonadhesive (Figure 6B). 
Indeed the reason why we have used PCL-PEG(1:4) is 
because the copolymers deposited under such conditions 
when deposited at low power can be cell nonadhesive 
while at higher powers they are dense and crosslinked 
and act as a barrier for leaching out of the drugs. In this 
work such multi-layer coatings have been deposited on 
biocompatible cellophane substrates which were flat, 
non-porous surfaces (2D). Cis-platinum loaded (118 
μgm/cm2) PCL-co-PEG coatings with optimized ratios 
of ε-CL/DEGME monomer feed in the plasma reactor 
were prepared for controlled cell death applications. 
The plasma treatments did not modify the flexibility 
and appearance of the membranes. As demonstrated 
by SEM, the copolymer layer was identifiable and 
the cancer cells forming the pods adhered well on the 
copolymer. These results suggest the biocompatibility 
and non-cytotoxicity of the membrane complex in the 
absence of drug. After incorporation of the drug, the 
membrane becomes cytotoxic. Cis-platinum-loaded 
cellophane implants were placed directly at the site of 
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mice liver, offering a controlled and local release of drug 
by means of polymer swelling and/ or dissolution and/or 
disintegration. The UV-Vis spectroscopic measurements 
were conducted on both cis-platinum solution in PBS 
(drug loading) and cis-platinum release in blood plasma. 
By using UV absorption measurements, we showed 
that cis-platinum reacted with proteins in the blood 
plasma and a derivatization technique is required for the 
quantification of cis-platinum in blood stream. By the 
different biochemical techniques, the reaction abilities 
of the platinum complexes such as cis-platinum to 
blood serum proteins have been reported before [25]. 
As compared to other proteins such as albumin and 
immunoglobulin, higher reaction (binding) ability of 
cis-platinum to hemoglobin (Hb) has been shown [26]. 
In our case of cis-platinum in blood plasma, a high 
absorbance of Hb was obtained at 410 nm as compared 
to the intensity of the cis-platinum for Pt+2 at 330 nm. 
After 10 days of implantation, the detection of traces of 
cis-platinum in the blood plasma might be difficult by 
means of UV absorption measurements without carrying 
out derivatization which result from the in vivo formation 
of cis-platinum-protein adducts via strong interactions 
between blood plasma and platinum ligands. Due to the 
complexity of the blood plasma and the low molecular 
absorptivity of cis-platinum in the UV region, the 
selective derivatization for the detection of cis-platinum 
in biological samples has been discussed by means of 
optical measurements of the platinum-ligand drugs [27].
Our previous in vitro study using plasma 
polymerized PCL-co-PEG coated cis-platinum for 
controlled release has confirmed the cytotoxic effects of 
cis-platinum to cancer cells [22].
Then the cellulose based polymer was covered 
with the multi-layered coating according to the 
procedure explained and was implanted on Glisson’s 
capsule of the liver. The in vivo measurements showed 
that all animals reacted against the implant and after 10 
days of post-implantation, inflammatory tissues were 
generated in the region of implants. Consequently, 
macroscopic and microscopic analysis demonstrated 
endogenous tissues containing the micro-vessels, 
fibrocytes, immune inflammatory cells, tissues matrix 
and fibrosis. In all experiments except when the implant 
Figure 4: Apoptotic cells in liver tissue sections were detected using TUNEL assay for untreated cellophane (Cello) A. 
plasma polymers + cellophane (pPCL-co-PEG-Cello) B. plasma polymers + Cis-platinum + cellophane (Cisp-pPCL-co-PEG-
Cello) C. and magnified image showing apoptotic cells D. Data are a typical fluorescent microscopic imaging of liver tissue sections 
under original magnification of × 100. Nuclei: blue, apoptosis cells: green.
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Figure 5: UV absorption spectrum of blood plasma for control, untreated cellophane (Cello), plasma polymers + 
cellophane (pPCL-co-PEG-Cello), and plasma polymers + Cis-platinum + cellophane (Cisp-pPCL-co-PEG-Cello).
Figure 6: Schematic of plasma polymerized multilayer coatings on cellophane for in vivo release of cis-platinum. A. 
Radio-Frequency Plasma Polymerization (RF-Plasma) of ε-Caprolactone and DEGDME for generation of PCL-PEG copolymer on the 
membrane (cellophane). B. Schematic of the multi-stack PCL-PEG coating for a tuneable release of entrapped drug layer (cis-platinum).
Oncotarget58128www.impactjournals.com/oncotarget
contained the drug, Glisson’s capsule was intact. In 
contrast, when implants contained the drug, the release 
induced the rupture of the Glisson’s capsule and 
consequently, the liver parenchyma was destroyed. The 
presence of apoptotic cells only in liver parenchyma in 
the presence of the implant which encapsulated the drug 
suggested the efficacy of nano thick multilayer drug 
delivery membrane. These implants provided the release 
of high amounts of the drug without any complication 
in surrounding organs stomach, spleen, diaphragm, 
and others digestive organs including renal toxicity 
(Supplementary Results, Figure S-1). All the 20 mice 
were alive and healthy on Day 10.
In the present work, the histological examination 
of the liver tissues which were in contact with cis-
platinum loaded plasma polymerized cellophane 
implants were showed hepatocellular vacuolization 
and cis-platinum induced inflammation of cells. As 
compared to untreated cellophane implanted on liver 
tissues, the apoptotic (TUNEL positive) cells were 
remained in the liver tissues which were in contact 
with cis-platinum loaded implants. Herein, we have 
shown the advantage of the one step, dry, clean, 
catalyst and solvent free soft plasma polymerized 
drug delivery system which can be prepared on a wide 
range of substrates and to achieve high purity materials 
and interfaces for in vitro and in vivo biological and 
clinical applications. In previous works, we used a 
wet chemical targeting method for ganciclovir-loaded 
albumin nanoparticles for intra ocular injection [28]. 
Co polymerization of the materials destined for 
nanoparticles generation, needed catalyser and solvent. 
Here, compared with traditional methods, we proposed 
plasma process which allows copolymerizing by means 
of a catalyst and solvent free process to regulate the drug 
release from a substrate.
However, we need further investigation to 
demonstrate the exact mechanism for loading and 
controlled release of cis-platinum induced hepatotoxicity 
and dose dependent effects on cancer tissues. In 
conclusion, low pressure plasma coating technique 
may be used to deposit coatings of uniform thicknesses 




A total of 20 female BALB/c mice (4 weeks old) 
were purchased from Charles River Laboratories (F 69592 
L'Arbresle) France and body weight ranging from 20 to 30 
g. All animals were maintained at the animal center for 2 
weeks of adaptive feeding prior the start of experiment. 
Animals were randomly divided into three experimental 
groups and a control group. The mice were caged in 
groups of five in an air-filtered laminar flow cabinet and 
fed with irradiated food and autoclaved reverse-osmosis 
treated water. All procedures were performed under 
sterile conditions in a laminar flow hood. Five animals 
for each group were used. The experimental protocol was 
approved by the Ethics Review Committee for Animal 
Experimentation of UPMC, France. All experimental 
protocols were performed in accordance with the European 
Convention for the protection of vertebrate animals used 
for experimental and other scientific purposes (Council of 
Europe, 1986, ETS No. 123).
Materials
ε-CL (Purity: 97%, MW: 114, Empirical formula: 
C6H10O2) and DEGME (Purity: 99.5%, MW: 134.17, linear 
formula: (CH3OCH2CH2)2O) were purchased from Sigma 
Aldrich, France and used in this study without further 
purifications. For the drug delivery implant applications, 
a 50 μm thick sheet of Cellulose bio-polymer was 
purchased from Humeau laboratories France. Cellophane 
substrates were cut to sizes of approximately 2 cm2 for all 
experiments.
Antineoplastic drug
Cisplatin or cis-diamminedichloroplatinum (II) 
(CDDP) (linear formula: PtCl2H6N2, MW: 300.05) was 
used as an antineoplastic (anticancer) drug in sterile 
aqueous solution. Each mL of cisplatin solution, was used 
for the current study contained 1 mg of cisplatin and 9 
mg sodium chloride in water (pH 3.5-4.5). For the in vivo 
drug release study, 20 μl of cisplatin solution of 1 mM 
concentration in 1X PBS was dropped onto cellophane 
substrates pre-coated with plasma polymerized PEG 
(pDEGME) and allowed to dry at room temperature. The 
cellophane slides (2 cm2) loaded with cisplatin (118 μgm/
cm2) were immersed in 1 mL of 1X PBS (pH 7.0) at 37 °C. 
The sample was agitated for 5 minute with a vortex mixer, 
then sonicated (Ultrasonic Cleaner, Fisher Scientific, 
France) in a room temperature water bath for 5 minute, 
and mixed with a vortex mixer for an additional minute. 
Afterwards, the supernatant was collected and the cisplatin 
loading was determined by UV Visible spectroscopic 
(SAFAS UVmc2, France) measurements. Spectral data 
was collected from 180-500 nm, (Supplementary Results, 
Figure S-2).
Plasma polymerization of PCL-co-PEG coatings
PCL and PEG (PCL-co-PEG) copolymer coatings 
were fabricated in a low pressure inductively excited 
radio frequency-tubular quartz plasma reactor system 
(5 cm diameter, 40 cm length, base pressure of 3x10-2 
mbar). The schematics of plasma deposition setup for 
PCL-PEG coatings, technical details of the process and 
in vitro characterization of cis-platinum release as well 
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as the cell-surface interactions have been provided in 
our earlier work [26]. Briefly, prior to each experimental 
run, the reactor was scrubbed and cleaned with 
detergent, organic solvents and dried using compressed 
air. After cleaning with solvent, the plasma reactor was 
reassembled and cleaned further with 30W argon plasma 
discharge at 0.5 mbar pressure for 30 min. The partial 
pressure ratio of the two monomer fed in the reactor was 
controlled by the flow rate of carrier gas (i.e. Ar), which 
was regulated and measured by electronic mass flow 
controllers (MKS instruments). The flow rate of carrier 
gas was varied from 5 to 20 sccm with the increment of 
5 sccm which was denoted by “1” for 5 sccm and “4” for 
20 sccm respectively. The total flow rate was varied from 
5 sccm to 25 sccm by keeping the operating pressure 
constant. The power was generated by Dressler Cesar RF 
generator which was delivered through the L-C matching 
network. The substrate is placed 9.0 cm below the coil. In 
the present work, we have deposited copolymer coatings 
for barrier layer at 20W CW (Continuous Wave) plasma 
which was then followed by deposition of a copolymer in 
a 1W PW (Pulse Wave). For the pulsed plasma discharge, 
the peak power (Ppk) was 25W and the duty cycle (DC = 
(ton / (ton+toff), where ton and toff were the ‘plasma ON’ and 
‘plasma OFF’ times respectively) was 4% to obtain the 
effective plasma power (Peff) which was 1W PW (ton = 
4ms and toff = 96ms). Plasma polymerization of organic 
monomers was carried out on biocompatible cellophane 
substrates. All the coatings were deposited for different 
time duration (td). After polymer deposition, the reactor 
was again evacuated to base pressure before the plasma 
polymerization system was vented to atmospheric 
pressure with air.
Determination of cis-platinum loading
The cis-platinum solution was dispersed on pDEGME 
deposited cellophane substrates. In order to ensure cis-
platinum recovery occurred from the cellophane implants, 
one implant was then cut into four individual pieces and 
submerged in 1 mL of 1X PBS (pH 7.0). The sample was 
agitated for 5 minute with a vortex mixer, then sonicated 
(Ultrasonic Cleaner, Fisher Scientific) in a room temperature 
water bath for 5 minute, and mixed with a vortex mixer for an 
additional minute. Afterwards, the supernatant was collected 
and the cis-platinum loading was determined by UV Visible 
spectroscopic (SAFAS UVmc2, France) measurements. 
Spectral data was collected from 180-500 nm.
Scanning electron microscopy
105/10μl of Suspended ovarian cancer cell line 
OVCAR-3 were deposited on a plasma polymerized 
glass and incubated for one minute then 2ml of RPMI 
medium (with 10% of Fetal Bovine Serum FBS, 1% of 
L-Glutamine and 1% of Streptomycin) were added to 
the well. All the samples were incubated at 37°C and 
5% CO2 for 48h. The culture medium was discarded and 
samples were washed. The samples were fixed in 2% 
glutaraldehyde and 1X phosphate buffer saline (PBS, 
pH 7.4) at room temperature for 1 hour, washed in 1X 
PBS and then post fixed in 1% osmium-1X PBS for 45 
min at room temperature and in dark conditions. After 
a final wash in 1X PBS, the samples were dehydrated 
in increasing concentrations of ethanol. Samples were 
dried by the critical point method with liquid CO2 and 
then sputter-coated with gold. They were observed 
with a S260 CAMBRIDGE scanning electron equipped 
with a LaB6 filament operating at 15kV and images 
were captured with the software “Orion” from (NCH 
Software).
Preparation of implants
A schematic of plasma deposited multilayer PCL-
co-PEG coatings on cis-platinum loaded cellophane 
for hepatic implantation is illustrated in Figure 6. For 
in vivo release of cis-platinum, the multilayer of plasma 
polymerized PCL-PEG copolymers were prepared on 
cellophane substrates as a multistep process discussed 
as follows: (i) 0th layer: a hydrophilic layer of plasma 
polymerized DEGME (pDEGME) coating was deposited 
on 2 cm2 cellophane substrates for 5 min at 1W effective 
power. (ii) Cis-platinum (118 μgm/cm2) solution was 
mobilized on pDEGME coated cellophane substrates. 
(iii) 1st layer: To avoid the direct exposure of the RF 
plasma, PCL-co-PEG (1:4) coatings were deposited on 
cis-platinum loaded cellophane substrates under mild 
conditions (Ppk=25 W, DC=4%, Peff=1 W, td=5 min). 
(iv) 2nd layer: The barrier layer coatings were deposited 
to encapsulate the drug under 20 W CW power for 10 
min. (v) 3rd layer: Finally, PCL-co-PEG (1:4) coatings 
were deposited on top of the barrier layer under mild 
conditions for controlled cell-surface interactions (Figure 
6). All the plasma deposited implants were prepared 1 
hr before the in vivo experiments. All the experimental 
conditions for preparation of implants are summarized 
in Table 1.
Membrane implantation
All 20 animals were anesthetized with 2% 
isoflurane in oxygen with mechanical ventilation for 
15 min. Each animal was fixed in a supine position. 
After skin disinfection with Betadine, a xifo-umbilical 
laparotomy was performed. A verification of the 
peritoneum and the abdominal cavity was realized and 
a self-retaining retractor was placed. If necessary, an 
Allis clamp type was placed on the xiphoid cartilage to 
improve exposure. The implants of cellophane (2 cm2) 
were placed above the left hepatic lobe, between the 
liver and the anterior face of the stomach. Untreated 
(Cello), plasma polymers (pPCL-co-PEG-Cello) and 
plasma polymers + Cis-platinum (Cisp-pPCL-co-PEG-
Oncotarget58130www.impactjournals.com/oncotarget
Cello) treated cellophane were implanted into animals 
in the three different experimental groups (Table 1). 
In the control group, all animals were remained as 
received. The absorbable compress Surgicel® (Oxidized 
regenerated cellulose) was used to completely cover 
the implant and avoid the displacement (migration). 
The peritoneum was closed with a continuous suture of 
Prolene 7/0 (Ethicon, Somerville, NJ) a non-absorbable 
over lock or metal clips was placed on the skin. After 
surgical procedure, the anesthetics were discontinued, 
and all animals were allowed to recover for 20 minutes 
in a box flushed with 100% oxygen and then placed in 
their home cages. After 10 days from implantation, all 
mice from both experimental and control groups were 
euthanized by CO2 inhalation. General conditions of 
the surrounding tissue and the implanted cellophane 
substrates were observed with the naked eye. The part 
of liver opposite to implant was removed, fixed in PAF 
(4%) and embedded in paraffin. The slides (4 micron) 
were produced and colored by hematein-eosin-safran 
(HES) according to classical methods in the anatomo-
pathogical laboratory. Histopathological study of liver 
tissues was performed
Terminal deoxynucleotidyl transferase dUTP 
nick-end labeling (TUNEL) assay
After 10 days of implantation, the apoptotic cells in 
the liver tissues adjacent to the cellophane implants were 
detected using TUNEL (Promega, Madison, WI) assay. In 
brief, the sections of liver tissues were deparaffinined and 
dehydrated, followed by permeabilization with 20 μg/mL 
proteinase K and 0.2% Triton X-100 in 1X PBS. The slides 
were then labeled with a TdT reaction mixture for 90 min 
and were mounted with a mounting solution containing 
4’, 6-diamidino-2-phenylindole (DAPI). The apoptotic 
cells (green) and cell nucleus (blue) was examined using a 
fluorescence microscopy.
In vivo release of cis-platinum
The blood samples were collected from the mice retro 
orbital sinus into Heparin tubes after 10 days of implantation. 
The sampled blood (0.3-0.5 mL) were centrifuged at 3000 
rpm for 10 min at 4°C to separate the plasma. Cis-platinum 
traces in the blood plasma was investigated using UV Vis 
Spectroscopic (SAFAS UV mc2, France) analysis. Spectral 
data was collected from 170-500 nm.
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